Followers | 35 |
Posts | 6308 |
Boards Moderated | 0 |
Alias Born | 02/09/2015 |
Sunday, February 22, 2015 1:00:29 PM
I reference here a wonderful post #91106, by the intrepid sclimmuno, in which he lists details about two drugs already approved, Dalbavancin, and Ortanavancin. Both are Brilacidin competitors, as you know, for skin infections. The first drug requires 2 iv doses, and the second one, only one IV dose. as compared to multi day Vancomycin treatment. Brilacidin did very well against Daptomycin, and offers the benefit of a one time dose. But one of the drugs referenced is also a single dose. Will a large company bide its time and let brilacidin prove it can beat those other already approved drugs? Or will they buy in ahead of time on the chance that Brilacidin will be better? There is no proof yet that Brilacidin can beat those other drugs that I know of- perhaps others have more info.
And Kevetrin:again,a couple of years away from proving its benefit in head to head trials. Human dosing still being worked out. IF the later cohorts show positive results there will be dramatic interest in this stock- but that has not been demonstrated in actual patients yet. This is a company that will not be shy to trumpet success- note PR released previously about a single patient, the one with ovarian CA. More PR from later cohorts will be needed to prove K really something special, and then of course, will need actual trial data to prove benefits.
In other words planning to retire at a share price of $30 or higher for CTIX is rather optimistic- at this point in time.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM